TMDIF vs. INFU, OBIO, ZJYL, ICAD, MBOT, GUTS, FONR, MGRM, NTRB, and SRTS
Should you be buying Titan Medical stock or one of its competitors? The main competitors of Titan Medical include InfuSystem (INFU), Orchestra BioMed (OBIO), Jin Medical International (ZJYL), iCAD (ICAD), Microbot Medical (MBOT), Fractyl Health (GUTS), FONAR (FONR), Monogram Orthopaedics (MGRM), Nutriband (NTRB), and Sensus Healthcare (SRTS). These companies are all part of the "medical equipment" industry.
Titan Medical vs. Its Competitors
Titan Medical (NASDAQ:TMDIF) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.
InfuSystem received 11 more outperform votes than Titan Medical when rated by MarketBeat users.
0.0% of Titan Medical shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 0.0% of Titan Medical shares are owned by insiders. Comparatively, 11.4% of InfuSystem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Titan Medical has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500.
InfuSystem has a net margin of 1.12% compared to Titan Medical's net margin of 0.00%. InfuSystem's return on equity of 2.78% beat Titan Medical's return on equity.
In the previous week, Titan Medical and Titan Medical both had 1 articles in the media. Titan Medical's average media sentiment score of 0.00 beat InfuSystem's score of -1.00 indicating that Titan Medical is being referred to more favorably in the media.
InfuSystem has a consensus price target of $13.00, suggesting a potential upside of 113.46%. Given InfuSystem's stronger consensus rating and higher probable upside, analysts clearly believe InfuSystem is more favorable than Titan Medical.
Titan Medical has higher earnings, but lower revenue than InfuSystem. Titan Medical is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.
Summary
InfuSystem beats Titan Medical on 13 of the 16 factors compared between the two stocks.
Get Titan Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for TMDIF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TMDIF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TMDIF vs. The Competition
Titan Medical Competitors List
Related Companies and Tools
This page (NASDAQ:TMDIF) was last updated on 6/12/2025 by MarketBeat.com Staff
